AI-Based Genetic Data Analysis

NGS ANALYSIS PLATFORM

Better Data for Better Health

Geneyx offers a superior NGS data analysis and interpretation platform, harnessing genetic data to guide digital insights for rare and germline disorders. Our AI-based analysis platform streamlines the diagnostics process, from the raw genetic data to the final clinical report. Geneyx develops unique technologies and utilizes diverse databases in the interpretation of WGS (Whole Genome Sequencing), WES, and gene panels. We aim to enrich disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and pharmaceutical organizations.

Play Video

From analysis to discovery

Accelerating Genetic Diagnosis and Research

Geneyx Analysis

Geneyx Test

Ready-To-Use Genetic Apps

Geneyx Research

Targeted Drug Discovery

Cases Analyzed

80000

Citations

Countries

TB of Genetic Data Analyzed

500

GENEYX ANALYSIS

For Hospitals & Labs

0 %

Double your diagnostic yield

0 %

Reduce your turn-around time

GENEYX ANALYSIS

For Hospitals & Labs

0 %

Double your diagnostic yield

0 %

Reduce your turn-around time

Knowledgebase

dozens of Key Data Sources

Integrating dozens of key data sources, the Knowledgebase empowers your Next Generation Sequencing analysis by highlighting associations between genes and phenotypes, providing supporting evidence for immediate evaluation, and automatically generating case reports.

Rapid and accurate phenotype-driven variant prioritization, supporting protein-coding genes and regulatory regions

Leveraging leading integrated regulatory region database.

Enabling rapid evaluation of candidate mutations and automated population of customized reports

Routinely updated with cutting-edge tools and the most recent, relevant data sources

Double the diagnostic yields.
Drastically reduced turnaround time.
Rapid, accurate interpretation.
The implications of this technology? Revolutionary.

Success Stories

See Geneyx In Action

Identifying novel mutations responsible for colon cancer predisposition

Prof Revital Kariv, M.D., and her team diagnose and treat patients with colon cancer. In many cases, they identify families with a clear predisposition to develop polyposis and thereafter colon cancer quite early in their lives, implying a strong inherited genetic background for the trait.

Increasing the accuracy and decreasing the time required for clinical genetic analysis

In 2017, The genetic team at the largest pediatric hospital in Europe, Prof Antonio Novelli and his team of geneticists used to analyze dozens of rare genetic disorder cases per month.

HEADLINES

News

November 9, 2021

Accenture Invests in Geneyx to Expand the Use of Genetic Data for Targeted and Personalized Therapeutics and Diagnostics

Marchell Gillis

NEW YORK--(BUSINESS WIRE)--Accenture (NYSE: ACN) has made a strategic investment, through Accenture Ventures, in Geneyx Genomex Ltd. (Geneyx), an Israel-based developer of genomic analysis and interpretation software. Geneyx helps improve patient outcomes associated with hereditary and rare diseases by providing disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and pharmaceutical organizations.

November 10, 2021

Geneyx Genomex Closes $6.5M Seed Financing Roun

staff reporter

NEW YORK – Geneyx Genomex said Tuesday that it has closed a seed financing round worth approximately $6.5 million. Capri Ventures and Accenture Ventures led the round. The firm, which is based in Herzliya, Israel, and Foster City, California, also said that it has joined Accenture Ventures' Project Spotlight, a program that helps connect software startups with major public companies.

October 10, 2020

Geneyx Genomex Acquires NGS Sequencing Analysis Firm Toldot Genetics

staff reporter

NEW YORK – Geneyx Genomex said Monday that it has acquired Toldot Genetics. Geneyx acquired Toldot from biomedical informatics firm BATM Advanced Communications and several minority shareholders, who in return received a 5 percent equity stake in Geneyx. Additional terms of the deal were not disclosed. Geneyx, an Israel-based developer of genomic analysis and interpretation software, will integrate Toldot’s TGex next-generation

April 8, 2020

Israeli Consortium Launches Patient Sequencing Study to Uncover COVID-19 Genetic Risk Factors

NEW YORK – Geneyx Genomex said Monday that it has acquired Toldot Genetics. Geneyx acquired Toldot from biomedical informatics firm BATM Advanced Communications and several minority shareholders, who in return received a 5 percent equity stake in Geneyx. Additional terms of the deal were not disclosed. Geneyx, an Israel-based developer of genomic analysis and interpretation software, will integrate Toldot’s TGex next-generation

Accenture Invests in Geneyx to Expand the Use of Genetic Data for Targeted and Personalized Therapeutics and Diagnostics

Marchell Gillis

NEW YORK--(BUSINESS WIRE)--Accenture (NYSE: ACN) has made a strategic investment, through Accenture Ventures, in Geneyx Genomex Ltd. (Geneyx), an Israel-based developer of genomic analysis and interpretation software. Geneyx helps improve patient outcomes associated with hereditary and rare diseases by providing disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and pharmaceutical organizations.

November 10, 2021

Geneyx Genomex Closes $6.5M Seed Financing Roun

staff reporter

NEW YORK – Geneyx Genomex said Tuesday that it has closed a seed financing round worth approximately $6.5 million. Capri Ventures and Accenture Ventures led the round. The firm, which is based in Herzliya, Israel, and Foster City, California, also said that it has joined Accenture Ventures' Project Spotlight, a program that helps connect software startups with major public companies.

October 10, 2020

Geneyx Genomex Acquires NGS Sequencing Analysis Firm Toldot Genetics

staff reporter

NEW YORK – Geneyx Genomex said Monday that it has acquired Toldot Genetics. Geneyx acquired Toldot from biomedical informatics firm BATM Advanced Communications and several minority shareholders, who in return received a 5 percent equity stake in Geneyx. Additional terms of the deal were not disclosed. Geneyx, an Israel-based developer of genomic analysis and interpretation software, will integrate Toldot’s TGex next-generation

April 8, 2020

Israeli Consortium Launches Patient Sequencing Study to Uncover COVID-19 Genetic Risk Factors

NEW YORK – Geneyx Genomex said Monday that it has acquired Toldot Genetics. Geneyx acquired Toldot from biomedical informatics firm BATM Advanced Communications and several minority shareholders, who in return received a 5 percent equity stake in Geneyx. Additional terms of the deal were not disclosed. Geneyx, an Israel-based developer of genomic analysis and interpretation software, will integrate Toldot’s TGex next-generation

NGS ANALYSIS PLATFORM

Better Data for Better Health

From analysis to discovery

Accelerating Genetic Diagnosis and Research